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The incidence of empyema has reportedly increased in some high-
income countries since the introduction of childhood seven-valent 
pneumococcal conjugate vaccine (PCV),[1-4] although there is a 
paucity of such data from low- and middle-income settings. Recent 
studies from South Africa (SA) and the USA suggested a decrease in 
the incidence of empyema since the introduction of 13-valent PCV. [5,6] 
Nonetheless, Streptococcus pneumoniae (serotypes 1, 3 and 19A) 
remains the commonest (10 - 48%) pathogen identified, followed by 
Staphylococcus aureus (8 - 19%), and less commonly Haemophilus 
influenzae and Mycoplasma pneumoniae.[3,5] In tuberculosis (TB)-
endemic settings, Mycobacterium tuberculosis (MTB) may account 
for 10 - 14% of cases.[5] However, studies in high-income countries 
indicate that in most instances the aetiology of the empyema may be 
unknown, as <30% of blood, pleural fluid or sputum cultures yield 
an organism.[3] The use of molecular techniques has been shown to 
improve diagnostic yield.[4]
The management of empyema remains challenging, even in high-
income countries.[3] Antibiotics alone have been recommended 
in children with no respiratory compromise, and fibrinolytics are 
recommended with either pigtail or intercostal drain (ICD) insertion 
in patients with respiratory compromise or failure to respond to 
antibiotics. Early video-assisted thorascopic surgery (VATS) for 
drainage, used as first-line treatment, has not been shown to improve 
outcomes at 6 months compared with use of an ICD and fibrino-
lytics. [7,8] The use of fibrinolytics may reduce the need for more 
invasive and expensive surgical options.
Objectives
To describe the clinical epidemiology of empyema at a secondary-
tertiary hospital with a paediatric pulmonology referral service, in a 
setting of high HIV and TB prevalence.
Methods
A retrospective descriptive study was undertaken in children aged 
<14 years at Chris Hani Baragwanath Academic Hospital (CHBAH) 
over the 5-year period January 2012 - December 2016. CHBAH is 
a secondary-tertiary academic hospital situated in Soweto, a peri-
urban and mostly low-income township south of Johannesburg, 
SA. In addition to providing a paediatric service to the residents 
of Soweto, this hospital is the referral centre for hospitals in the 
surrounding areas. The prevalence of childhood HIV infection is 3 - 
4%, while 30% of newborns are HIV-exposed in this setting.[9]
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Background. There is a paucity of information on empyema in children from low- and middle-income countries since the introduction of 
the pneumococcal conjugate vaccine.
Objectives. To describe the aetiology and management of empyema in a setting of high HIV and tuberculosis (TB) prevalence.
Methods. A retrospective descriptive study was undertaken between January 2012 and December 2016 in children aged <14 years at a large 
secondary-tertiary referral hospital in Soweto, South Africa. Cases of empyema were identified through administrative databases. Clinical, 
laboratory and radiological data were extracted from patient records.
Results. We identified 65 cases of protocol-defined empyema, including 22 (33.8%) referred from surrounding hospitals. The median age at 
presentation was 53.2 months (interquartile range (IQR) 19.5 - 103.6). Thirteen patients (20.0%) were HIV-infected and 6 (9.2%) were HIV-
exposed but uninfected. A bacterial pathogen was identified in 36 cases (55.3%). The commonest causative organisms were Staphylococcus 
aureus (14/65, 21.5%) and Streptococcus pneumoniae (5/65, 7.7%). Treatment for TB, initiated in 28 children (43.1%), was more frequent in 
HIV-infected children (10/13, 76.9%) (p=0.011); however, microbiological evidence of TB was present in only 5 cases (7.7%). Forty-three 
children (66.2%) had an intercostal drain (ICD) inserted and 16 (24.6%) a pigtail percutaneous catheter, while a fibrinolytic was only used 
in 6 (10.2%). Eight children (12.3%) had a thoracotomy and 7 (10.7%) had video-assisted thorascopic drainage, all of whom had a prior 
ICD inserted, a median of 20 days (IQR 10 - 33) before surgery. Overall, 7 children (10.8%) were mechanically ventilated and 1 (1.5%) died.
Conclusions. Our study showed a dominance of S. aureus as a cause of empyema. A high proportion of HIV-infected children with 
empyema were initiated on TB treatment, highlighting challenges in managing TB-HIV co-infection. Although fibrinolytics or early surgery 
are recommended, neither practice was common in this setting.
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The paediatric pulmonology department at CHBAH was estab-
lished in February 2011. Children admitted or referred from other 
hospitals with empyema are admitted to the general paediatric 
wards and management includes referral to the pulmonologist. 
Doctors diagnosed empyema by visualising purulent material 
drained from the pleural space or on ultrasound and/or a computed 
tomography (CT) scan. There was no standardised treatment 
protocol for the management of empyema; however, all children 
with empyema receive broad-spectrum antibiotics (ampicillin and 
gentamicin, or co-amoxiclav). Other treatment modalities include 
an ICD, a pigtail drain, fibrinolytics, VATS or thoracotomy with 
drainage/cleanout.
Children diagnosed with empyema at CHBAH over the past 5 years 
were identified through the pulmonology and discharge summary 
administrative databases. Clinical, laboratory and radiological 
information was extracted from patient records. Laboratory markers 
such as a full blood count, C-reactive protein, blood cultures, sputum 
cultures, fluid biochemistry and culture were obtained from the 
National Health Laboratory Service Track-Care system. Sputum or 
gastric washings were routinely cultured for MTB but not for other 
micro-organisms.
Statistical analysis
Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) criteria were used for the inclusion of cases 
that met the case definition. Empyema was defined as the visualising 
of purulent/pus/turbid fluid after thoracocentesis or drainage; an 
ultrasound scan of the chest demonstrating fibrin strands, loculations 
or dense fluid; a CT scan demonstrating hyperdense fluid or splitting 
of the pleura; a neutrophil predominance (≥2+) on pleural fluid 
microscopy; or a bacterial organism identified on culture of the 
pleural fluid. The incidence was calculated for patients who presented 
directly to CHBAH (patients not resident in Soweto were excluded 
in the incidence calculation), and expressed as cases per 100 000 
population for Soweto and surrounding areas as per Statistics South 
Africa population estimates (Gauteng subdistrict population mid-
year estimates 2005 - 2016: personal communication from Mrs 
Andy Valashiya, Directorate: Information Management, National 
Department of Health, 13 May 2013). Probable causative pathogens 
were identified using pleural, blood or sputum cultures, or molecular 
techniques in two cases.
Data were described using the following statistical methods: the 
median and interquartile range (IQR) were reported for continuous 
variables and frequencies were reported for categorical variables. The 
Mann-Whitney test was used to compare continuous variables and 
Pearson’s χ2 test or Fisher’s exact test for categorical variables. Data 
were analysed using Stata version 13.1 (StataCorp, USA).
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M170152).
Results
Demographic details
Over the 5-year period, 65 of the 154 screened database cases met the 
case definition of empyema (Fig. 1). Overall, 37 patients (56.9%) were 
male and the median age at diagnosis was 53.2 months (IQR 19.5 - 
103.6) (Table 1). Thirteen children (20.0%) were HIV-infected and 
6 (9.1%) were aged <18 months and HIV-exposed but uninfected. 
The median weight-for-age z-score was –1.3 (IQR –2.1 - –0.2) and 
the median height-for-age z-score was –1.6 (IQR –2.7 - –0.8). The 
incidence of empyema was estimated as 1.46 (95% confidence interval 
(CI) 1.05 - 1.97) per 100 000 population and 3.40 (95% CI 2.45 - 4.59) 
per 1 000 hospitalised cases of acute lower respiratory infection, and 
did not differ significantly over the study period (p=0.19). A third of 
the patients (22, 33.8%) were referred from surrounding hospitals, 
with a median time to referral of 14 days (IQR 9 - 19).
Aetiological agents
A bacterial pathogen was identified in 36 cases (55.3%), 34 on culture 
of blood or pleural fluid and 2 isolated by multiplex polymerase 
chain reaction (Fig. 2). The most common organism isolated was 
Staphylococcus aureus (n=14, 21.5%) followed by Streptococcus 
pneumoniae (n=5, 7.7%), MTB (n=5, 7.7%) and Klebsiella pneumoniae 
(n=3, 4.6%). One patient (1.5%) grew both MTB and S. aureus on 
pleural fluid, while the other 4 cases of MTB were cultured on gastric 
washings or sputum samples.
Because 28 children (43.1%) were treated for TB, in an exploratory 
analysis we compared clinical characteristics between those treated 
for TB and those not treated (Table 1). Treatment for TB was 
initiated more commonly in HIV-infected (10/13, 76.9%) than HIV-
uninfected children (17/51, 33.3%) (p=0.011).
Laboratory findings
The median white cell count was 19.8 × 109/L (IQR 13.6 - 27.3) 
(Table 2). Forty-five patients (69.2%) had neutrophilia, with a 
median neutrophil count of 13.5 × 109/L (IQR 7.3 - 19.2). Although 
Database searches for parapneumonic, 
pleural eusion, pyopneumothorax, 
empyema and abscess
N=154
After duplicates removed and age limits
n=151
Excluded, n=86:
• Abscess only, n=19
• Not hospitalised, n=14
• Chylothorax, n=4
• Lung cysts, n=2
• Hydatid cysts, n=2
• Did not meet case denition, n=45
Patients meeting case denition
n=65
Fig. 1. Flow diagram of cases meeting case definition.
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53 patients (81.5%) had monocytosis, no 
significant differ ence was noted between 
those who were treated for TB and those 
who were not. The C-reactive protein level 
was raised in all cases, with a median of 143 
mg/L (IQR  71 - 294). Children who were 
treated for TB had a significantly higher 
pleural fluid protein level (58 g/L) than 
those who were not (50  g/L) (p=0.030), 
whereas pleural fluid lactate dehydrogenase 
was lower in those who were treated for TB 
(965 U/L v. 2 243  U/L) (p=0.004).
Treatment modalities and outcomes
The median duration of hospitalisation 
was 18 days (IQR 12 - 24). All children 
were initiated on antibiotic therapy and 59 
(90.8%) required pleural drainage. Forty-
three children (66.2%) had an ICD inserted 
and 16 (24.6%) had a pigtail percutaneous 
catheter inserted; however, fibrinolytics were 
only documented in 6 (9.2%). Eight children 
(12.3%) had a thoracotomy and 7 (10.7%) 
had VATS, all of whom had a prior drain 
inserted with a median of 20 days (IQR 10 - 
33) from admission to surgery. Seven children 
(10.8%) required intubation and ventilation 
and 1 died (case fatality ratio 1.5%).
Discussion
In this low- to middle-income setting, 
the commonest causes of empyema were 
S.  aureus, S. pneumoniae and MTB. The 
lower prevalence of S. pneumoniae empy-
ema may be attributable in part to the 
introduction and  high coverage rates 
(>99%) of the 13-valent PCV since 2011 in 
this setting.[5,6,10] How ever, our study was 
limited because we relied mainly on culture-
confirmed diagnosis, and studies using 
molecular techniques continue to show a 
higher prevalence of S.  pneumoniae as the 
predominant pathogen causing empyema.[4] 
Importantly, antibiotics initiated in children 
with empyema should provide S. aureus and 
S. pneumoniae cover.
Another important finding of our study 
was the large proportion of patients who 
were initiated on TB therapy despite only 
a few being microbiologically confirmed. 
Most children have paucibacillary TB, and 
culture sensitivity is generally lower than 
in adults.[11,12] Diagnosing TB is challenging 
in children, and clinicians often rely on 
clinical symptoms, radiological evidence 
and immunological testing, none of which 
are specific.[11] This is further compounded 
in HIV-infected children because of an 
overlap between clinical and radiological 
evidence of TB and other opportunistic or 
chronic infections.[13] This could in part 
explain our findings where most HIV-
infected children were initiated on TB 
treatment. A study in Cape Town, SA, where 
the burden of TB is among the highest 
in the world, reported a prevalence of 
TB empyema of 10 - 14%. [5] Furthermore, 
culture-confirmed TB has been reported in 
8 - 43% of children with acute pneumonia, 
and co-infection with other pathogens 
may occur in a quarter of children.[12,14] In 
settings with a high TB burden, concurrent 
diagnostic evaluation for MTB as well as 
other organisms is therefore necessary in 
children with empyema.
The management of empyema includes 
fluid drainage if there is no clinical 
response to antibiotic therapy, or in cases 
of respiratory compromise.[3] In our study, 
although the majority of cases required 
drainage, only a few received fibrinolytic 
therapy. This is in contrast to high-income 
settings, where the use of fibrinolytics is 
recommended with intercostal drainage, as 
the outcome is similar to that of VATS.[7,8,15] 
Furthermore, use of fibrinolytic therapy in 
low-resource settings may have additional 
value because the shortage of surgeons and 
postoperative intensive care facilities delays 
surgical intervention.
Table 1. Demographic characteristics of children with empyema
Overall (N=65) TB treatment (N=28) No TB treatment (N=37) p-value*
Male gender, n (%) 37 (56.9) 20 (71.4) 17 (45.9) 0.040
Age, median (IQR) 53.2 (19.5 - 103.6) 60.2 (21.7 - 111.4) 31.0 (16.7 - 99.0) 0.311
HIV status, n (%) 0.011†
Infected 13 (20.0) 10 (35.7) 3 (8.1)
Exposed, uninfected 6 (9.1) 1 (3.4) 5 (13.5)
Uninfected 45 (69.2) 16 (57.1) 29 (78.3)
Unknown 1 (1.5) 1 (3.6) -
WAZ, median (IQR) n=54
–1.3 (–2.1 - –0.2)
n=23
–1.3 (–2.2 - –0.1)
n=31
–1.3 (–2.1 - –0.2)
0.979
HFAZ, median (IQR) n=55
–1.6 (–2.7 - –0.8)
n=24
–2.2 (–2.7 - –0.9)
n=31
–1.1 (–2.8 - –0.3)
0.382
TB = tuberculosis; IQR = interquartile range; WAZ = weight-for-age z-score; HFAZ = height-for-age z-score.
*p-value comparing children initiated and not initiated on TB treatment, using χ2, Fisher’s exact or Wilcoxon rank-sum (Mann-Whitney) tests.
†Fisher’s exact test was used to compare proportions of HIV-infected with HIV-uninfected children only. The comparison did not include exposed but uninfected children and those of unknown 
HIV status.
Fig. 2. Bacterial pathogens identified on blood or pleural fluid. ‘Other organisms’ identified on pleural 
fluid (n=10 patients) were Acinetobacter species and Serratia marcescens (n=1), Enterococcus faecalis 
(n=1), E. faecium (n=1), streptococcal species (n=1), Ochrobactrum anthropi and Acinetobacter 
baumannii (n=1), Kluvera intermedia (n=1), Streptococcus anginosus (n=1), Citrobacter koserii 
(n=1), Morganella morganii (n=1), and normal respiratory flora (n=1). On blood culture (n=4 
patients), Salmonella spp.(n=1), S. viridans (n=2) and Corynebacterium (n=1) were identified.
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Study limitations
Our study had several limitations, including incomplete or missing 
records. We therefore used a strict case definition for empyema and 
are likely to have underestimated the incidence in this setting. Despite 
the high culture positivity rate (55.4%), a large proportion (21.5%) of 
organisms isolated from culture were probable contaminants. A major 
limitation was the lack of access to molecular testing to improve 
diagnostic yield. Furthermore, as no protocol for the management 
of empyema existed in our setting, investigations and management, 
including those related to TB, were at the discretion of the treating 
clinician. Additionally, the high rates of TB therapy in our study must 
be taken in the context of delayed referral and suboptimal management 
of empyema, possibly biasing clinicians to initiate therapy based on 
delayed recovery. A comparison between patients receiving PCV7 
and those who received PCV13 could not be made, as the vaccination 
information was unavailable. We did not have accurate data on the 
duration and choice of antibiotics or long-term outcome data.
Conclusions
This study shows that S. aureus, S. pneumoniae and MTB were the 
commonest causes of empyema. Furthermore, in settings with a high 
burden of TB or HIV, thorough investigations for concomitant TB 
infection are necessary in children presenting with empyema.
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Table 2. Laboratory characteristics of children with empyema
Overall TB treatment No TB treatment p-value*
Leucocytes (× 109/L), median (IQR) n=64
19.8 (13.6 - 27.3)
n=27
19.0 (9.1 - 23.1)
n=37
20.0 (15.9 - 28.0)
0.176
Neutrophils (× 109/L), median (IQR) n=61
13.5 (7.3 - 19.2)
n=25
10.4 (7.3 - 17.2)
n=36
14.2 (7.5 - 23.1)
0.268
Lymphocytes (× 109/L), median (IQR) n=61
3.3 (2.0 - 5.3)
n=25
3.2 (1.8 - 5.1)
n=36
3.5 (2.1 - 5.7)
0.692
Monocytes (× 109/L), median (IQR) n=61
1.6 (0.9 - 2.5)
n=25
1.5 (0.9 - 2.3)
n=36
1.6 (1.1 - 2.7)
0.450
CRP (mg/L), median (IQR) n=49
143 (71 - 294)
n=19
97 (71 - 273)
n=30
162 (64 - 309)
0.862
Pleural fluid protein (g/L), median (IQR) n=29
51 (46 - 58)
n=9
58 (53 - 68)
n=20
50 (44 - 53)
0.030
Pleural fluid LDH (U/L), median (IQR) n=30
2 000 (1 321 - 2 902)
n=10
965 (289 - 2 000)
n=20
2 243 (2 000 - 3 618)
0.004
TB = tuberculosis; IQR = interquartile range; CRP = C-reactive protein; LDH = lactate dehydrogenase.
*p-value comparing children initiated and not initiated on TB treatment, using χ2, Fisher’s exact or Wilcoxon rank-sum (Mann-Whitney) tests.
